Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...
Myriad Genetics: Navigating Through A Setback
Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...
Myriad Genetics announces hereditary cancer risk assessment study published
Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening ...
Myriad Genetics stock hits 52-week low at $12.16 amid market challenges
Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...
MedCity News9d
Myriad Genetics
BRCA gene testing has continued to be an issue in the courts. But a patent infringement case between Myriad Genetics (Nasdaq: MYGN) and GenebyGene has been resolved and offers some guidance on the ...
Nasdaq14d
Myriad Genetics Partners with Hannah Storm to Promote Breast Cancer Risk Awareness Through Genetic Testing
was caught early due to additional screening, Storm aims to encourage discussions about hereditary cancers through her social media platforms. Myriad Genetics aims to improve patient care by ...
Hosted on MSN13d
MYGN Stock Gains Following Collaboration With Hannah Storm
Myriad Genetics, Inc. MYGN recently announced an agreement with Hannah Storm, a nationally renowned sports broadcaster who ...
Yahoo Finance14d
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
Myriad Genetics, Inc. SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah ...
Yahoo Finance17d
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate ...
Medindia1d
Prostate Cancer: Are Genomic Tests the Future of Risk Assessment?
A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...
manilatimes2d
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that ...
CNN2d
Myriad Genetics, Inc.
Myriad Genetics, Inc. engages in the discovery ... The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing ...